secwatch.observer — SEC 8-K summary
======================================

Issuer:     Summit Therapeutics Inc. (SMMT)
CIK:        0001599298
Form:       8-K
Filed at:   2023-05-11T23:59:59+00:00
Accession:  0001599298-23-000055
Event type: earnings
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Summit Therapeutics reports Q1 net loss of $542.4M; first patient dosed in ivonescimab trial
--------------------------------------------------------------------------------

- Net loss of $542.4M for Q1 2023 includes $520.9M one-time in-process R&D expense for ivonescimab in-licensing.
- First US patient treated in Phase III HARMONi trial of ivonescimab in EGFR-mutated NSCLC; HARMONi-3 trial expected H2 2023.
- Cash and investments $241.9M at March 31, 2023, down from $648.6M at Dec 31, 2022; notes payable $100M due Sept 2024.
- Fully-subscribed rights offering raised $500M gross proceeds (476.2M shares at $1.05); used to repay $400M note to Chairman Duggan.
- Collaboration with Akeso closed Jan 2023; $500M upfront paid; Akeso eligible for up to $4.5B milestones and low double-digit royalties.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1599298/000159929823000055/0001599298-23-000055-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1599298/000159929823000055/smmt-20230511.htm
  HTML page:      https://secwatch.observer/filing/0001599298-23-000055

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer